Lee Rubin

Dr. Rubin is Professor, Stem Cell & Regenerative Biology, Harvard University & Director of Translational Medicine, Harvard Stem Cell Institute. Dr. Rubin has broad experience in both academia and industry, particularly in cell-based assays and drug discovery. Prior to coming to Harvard, he was Chief Scientific Officer of Curis, Inc., a Cambridge-based biotechnology company, where his group identified the first small molecule antagonist of the hedgehog signaling pathway that was developed by Genentech and now (as Erivedge) approved as oral treatment for basal cell carcinoma. At Harvard, much of his work is focused on finding key molecular mediators of neurodegenerative diseases. Dr. Rubin received his PhD in neuroscience from Rockefeller University with postdoctoral training, in Neuroscience at Harvard Medical School and Stanford University School of Medicine. Dr. Rubin leads research sponsored by Elevian at Harvard studying neurodegenerative preclinical models and circulating factors that regulate aging.